Core Insights - Corvus Pharmaceuticals will announce interim data from a Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024 [1] - A conference call and webcast will be held to discuss the clinical data, accessible via phone and the company's website [2] About Soquelitinib - Soquelitinib is an investigational oral small molecule drug that selectively inhibits ITK, impacting T cell differentiation and immune function [3] - The drug has shown potential in treating cancers and autoimmune diseases by shifting T cell differentiation towards regulatory cells [3] - A registrational Phase 3 trial for relapsed peripheral T cell lymphoma has been initiated based on positive Phase 1/1b results [3] About Corvus Pharmaceuticals - Corvus Pharmaceuticals is focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The company’s lead candidate is soquelitinib, with other clinical-stage candidates targeting different cancer indications [4]

BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quali ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Recent Price Strength Screen - The "Recent Price Strength" screen is a unique short-term trading strategy that helps identify stocks with strong fundamentals capable of maintaining an uptrend [2]. - Stocks that pass this screen are typically trading in the upper portion of their 52-week high-low range, indicating bullish sentiment [2]. Group 2: Corvus Pharmaceuticals (CRVS) - Corvus Pharmaceuticals is highlighted as a strong candidate for trend investors, having experienced a price increase of 105.3% over the past 12 weeks, indicating investor confidence in its potential upside [3]. - The stock has also seen an 18.2% price increase over the last four weeks, suggesting that the upward trend is still intact [4]. - Currently, CRVS is trading at 83% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 3: Fundamental Strength - CRVS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [6]. Group 4: Additional Opportunities - Besides CRVS, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [7]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [7].

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company’s lea ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ) in the spotlight. As you can see, the shares of this clinical stage biopharmaceutical company have soared in rece ...

Financial Data and Key Metrics Changes - Research and development expenses increased to $5.2 million in Q3 2024 from $4 million in Q3 2023, primarily due to higher clinical trial expenses for soquelitinib [7] - The net loss for Q3 2024 was $40.2 million, significantly higher than the net loss of $6 million in Q3 2023, which included a noncash loss from Angel Pharmaceuticals [7] - Cash, cash equivalents, and marketable securities totaled $41.7 million as of September 30, 2024, compared to $27.1 million at the end of 2023 [8] - The company anticipates that its cash runway extends into 2026, aided by the early exercise of common stock warrants [9] Business Line Data and Key Metrics Changes - Soquelitinib is advancing in multiple clinical trials, including a Phase III trial for peripheral T-cell lymphoma (PTCL) and a Phase I trial for atopic dermatitis [10][19] - The Phase I trial for atopic dermatitis is designed to enroll 64 patients, with the first cohort already completed and the second cohort currently enrolling [12][14] - The objective response rate for the Phase III PTCL trial remains at 39%, with a median progression-free survival (PFS) of 6.2 months [22] Market Data and Key Metrics Changes - The FDA has granted orphan drug designation and Fast Track designation for soquelitinib for the treatment of relapsed T-cell lymphoma [19] - The company is enrolling patients at multiple clinical sites for the PTCL trial, aiming for 40 to 50 centers across the U.S., Australia, Canada, and South Korea [20] Company Strategy and Development Direction - The company is focusing on advancing soquelitinib for both oncology and autoimmune diseases, with plans to initiate a solid tumor trial in early 2025 [23][28] - There is a strong emphasis on the potential of soquelitinib in treating a broad range of immune diseases and cancers, supported by preclinical data [18] - The company is also developing second- and third-generation ITK inhibitors targeting various immunology indications, including asthma and inflammatory bowel disease [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of the atopic dermatitis trial and the potential advantages of soquelitinib, including its oral administration and safety profile [18] - The company plans to present complete data from the atopic dermatitis trial in December and anticipates further data in early 2025 [28] - Management highlighted the importance of the upcoming clinical milestones and the potential for ITK inhibition in immunology and cancer [29] Other Important Information - The company is actively monitoring patients in ongoing trials and has reported sustained responses in several patients [21] - The mechanism of action of soquelitinib is believed to induce an immune response that can handle a broad spectrum of tumors, potentially reducing the emergence of resistance [46] Q&A Session Summary Question: Can you comment on the kinetics of ITK inhibition on clinical scores in atopic dermatitis? - Management noted that improvements are observed within the first week, with expectations for durable effects based on the drug's mechanism of action [32] Question: What is the follow-up time period for the cohorts in the atopic dermatitis trial? - Management confirmed that 28-day data will be reported in December, with complete follow-up for Cohort 1 and partial follow-up for Cohort 2 [36] Question: What is the typical prior therapy for patients enrolled in the atopic dermatitis trial? - Most patients have failed topical therapies, with some not having failed systemic therapies yet [42] Question: How does the company plan to differentiate dosing between oncology and autoimmune diseases? - Management indicated that continuous treatment may not be necessary for atopic dermatitis, unlike cancer treatments [52] Question: What are the criteria for success in the Phase III PTCL trial? - The statistical plan aims for a 1.5-month improvement in PFS over the control arm, with a hazard ratio of about 0.56 [61]

Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLO ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharm ...

BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Ara ...